China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
REDWOOD CITY, Calif., Feb. 08, 2017 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced that Paul J. Hastings, OncoMed’s Chairman and Chief Executive Officer, will speak at two upcoming investor conferences being held in New York, NY.
BIO CEO and Investor Conference, February 13-14, 2017
- On Tuesday, February 14, 2017, Mr. Hastings will present a corporate update at 2:30 pm EST.
2017 Leerink Global Healthcare Conference, February 15-16, 2017
- On Thursday, February 16, 2017 at 2:00 pm EST, Mr. Hastings, along with John Lewicki, Ph.D, Executive Vice President, Research and Development, will participate in a fireside chat to discuss recent corporate developments.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, recurrence and metastases. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company’s strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc, as well as continuing to pursue new drug discovery research efforts. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Contact: OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications [email protected] (650) 995-8373
